WeVote
Log In

Bill

Bill

HB 3759

IL FDA-PROHIBIT DRUG PAY OFF

104th Regular Session Introduced by Bob Rita

Illinois bill prohibits drug makers from paying to delay generic/biosimilar market entry, aiming to reduce prescription costs through faster generic competition.

Rule 19(a) / Re-referred to Rules Committee
0
WeVote Research Nonpartisan
Bill Summary · HB 3759

Legislative bill overview

HB 3759 prohibits pharmaceutical companies from making payments or entering into agreements with pharmacy benefit managers (PBMs) that could delay or prevent patients from accessing lower-cost generic drugs or biosimilars. The bill aims to eliminate "pay-for-delay" schemes where drug manufacturers pay competitors to keep cheaper alternatives off the market longer.

Why is this important

Pay-for-delay agreements artificially extend patent protections and delay generic competition, keeping drug prices artificially high for Illinois consumers and state health programs. By blocking these practices, the bill could reduce prescription drug costs and accelerate patient access to more affordable medications, potentially saving individuals and the state significant healthcare expenses.

Potential points of contention

  • Industry opposition: Pharmaceutical companies may argue restrictions limit legitimate business negotiations and could reduce R&D investment incentives
  • PBM relationships: The bill affects complex commercial relationships between drug makers and PBMs, which manage drug formularies and pricing for insurers
  • Federal preemption questions: Similar practices are addressed under federal law; clarification needed on whether state-level restrictions create conflicts or gaps
  • Implementation clarity: The bill's exact definitions of prohibited "payments" and enforcement mechanisms may need refinement to avoid unintended consequences

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.